DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Retinitis Pigmentosa
Conditions
Retinitis Pigmentosa
Trial Timeline
Oct 23, 2025 → Oct 31, 2032
NCT ID
NCT06891885About DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3 is a phase 1/2 stage product being developed by Sumitomo Pharma for Retinitis Pigmentosa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06891885. Target conditions include Retinitis Pigmentosa.
What happened to similar drugs?
0 of 3 similar drugs in Retinitis Pigmentosa were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06891885 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Retinitis Pigmentosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AGN-151597 | AbbVie | Phase 1/2 | 32 |
| CPK850 | Novartis | Phase 1/2 | 36 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 40 |
| Valganciclovir | Roche | Pre-clinical | 26 |
| Foscarnet sodium + Ganciclovir | Roche | Phase 1 | 29 |
| Ganciclovir | Roche | Phase 1 | 29 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Phase 2 | 35 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Zidovudine + Sargramostim + Ganciclovir | Roche | Pre-clinical | 26 |
| Zidovudine + Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Interferon beta-1b + Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Pre-clinical | 26 |
| Ganciclovir | Roche | Phase 3 | 40 |
| Valganciclovir | Roche | Phase 3 | 36 |
| Cidofovir + Probenecid | Gilead Sciences | Pre-clinical | 26 |
| Cidofovir + Probenecid | Gilead Sciences | Pre-clinical | 26 |